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Liver stiffness is not associated with short- and long-term plasma 
HIV RNA replication in immunocompetent patients with HIV 
infection and with HIV/HCV coinfection
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Marzia Maria Franzettib, Anna Maria Cattelanb, Daniela Zagoa, Mario Crucianic, Massimo Andreonid, 
Sara Piovesana, Giorgio Palùa, Alfredo Albertia
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Abstract Background Human immunodeficiency virus (HIV) may be directly responsible for liver damage 
but there are contrasting data regarding the influence of detectable plasma viremia. We analyzed the 
influence of plasma HIV RNA (pHIV) detectability and of other clinical and viro-immunological 
variables on liver stiffness (LS) measurement in adult immunocompetent HIV-monoinfected 
patients and in patients coinfected with hepatitis C virus (HCV).
Methods Logistic regression analysis was performed using the value of LS>7.1 kPa as the 
dependent variable. A  linear regression model was applied using LS measurement after log10 
transformation (lkpa) as the dependent variable and we analyzed the predicted values versus the 
observed lkpa values; pHIV was classified as detectable or undetectable in the 12- and 36-month 
study periods before LS measurement.
Results We studied 251 patients (178 with HIV monoinfection), most of whom were on antiviral 
treatment; 36-month study time was available for 154 subjects. The mean CD4+ cell count was 
634  cells/mm3 in HIV-monoinfected patients and 606  cells/mm3 in coinfected patients. No 
difference in LS was found between patients with detectable or undetectable pHIV in either 
the 12-  or the 36-month study period before transient elastography. The mean LS was higher 
in HIV/HCV coinfected patients (P<0.0001) than in the HIV-monoinfected subjects; lkpa was 
positively correlated with HCV coinfection (P<0.0001) and aspartate aminotransferase levels 
(P<0.0001). Detectable pHIV failed to reach significance. Eight HIV-monoinfected patients had 
a predicted LS measurement lower than the observed one, while eight patients had the opposite 
result.
Conclusion LS was not correlated with ongoing HIV replication during the 12- and 36-month 
study periods in immunocompetent HIV-monoinfected and HIV/HCV-coinfected patients.
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Introduction
Chronic liver disease is a major cause of morbidity and 
mortality in human immunodeficiency virus (HIV)-positive 
patients, and coinfection with hepatitis C virus (HCV) is one 
of the most clinically important comorbidities [1]. However, 
many other factors, such as alcohol abuse, drug-related 
hepatotoxicity and nonalcoholic fatty liver disease, may also 
be responsible for liver damage [2,3]. This scenario is evolving 
as a result of the availability of direct-acting antivirals for the 
treatment of HCV infection and the current minimal exposure 
to antiretroviral drugs with a potentially hepatotoxic profile, 
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such as didanosine, stavudine or zidovudine [4-6]. HIV 
may be directly responsible for liver damage; Kupffer cells, 
hepatocytes, and human stellate cells (HSCs) do not express 
CD4 receptors, and HIV cannot infect these cells, but the 
virus can stimulate HSCs through a C-C chemokine receptor 
type  5-  or C-X-C chemokine receptor type  4-dependent 
pathway. HSCs are key cells involved in the progression of 
fibrosis: transforming growth factor-β, secreted by human 
peripheral blood mononuclear cells infected by HIV-1, was 
found to promote HSC modulation in an in vitro model [7,8]. 
Updated guidelines recommend that antiretroviral treatment 
(ART) should be started in all HIV-infected subjects with 
detectable plasma HIV viremia, regardless of CD4+ cell count; 
successful plasma HIV viremia suppression is achieved in most 
patients, but long-term efficacy may be suboptimal [6,9].
Liver fibrosis in HIV-positive patients is a multifactorial 
process; parameters modifiable over time (e.g.,  HBV-DNA 
and HCV-RNA detectability or undetectability) or parameters 
not modifiable over time (e.g.,  sex) may influence liver 
fibrosis [3,10,11]. The measurement of liver stiffness (LS) 
by transient elastography (TE) represents a rapid and 
noninvasive method for predicting liver fibrosis, and the 
result, which is expressed in kilopascals (kPa), is available 
immediately; this imaging modality is highly accurate in the 
detection of moderate fibrosis and cirrhosis in patients with 
HIV/HCV coinfection [12]. Abnormal LS values were found 
in a percentage of HIV-monoinfected patients, ranging from 
41.9% (LS values >5.3 kPa were considered abnormal) to 11.2% 
(LS values ≥7.2 kPa were considered abnormal) [13-15].
TE was shown to be more reliable than the aspartate 
aminotransferase (AST)-to-platelet ratio index and the 
Fibrosis-4 score (FIB-4) in the staging of liver fibrosis in 
HIV/HCV coinfected patients; both indices include platelet 
count, which may be lower in viremic HIV-positive patients 
because of HIV-related thrombocytopenia [16,17]. The 
first aim of this study was to describe the demographic and 
viro-immunological parameters that influence TE results in a 
cohort of immunocompetent HIV-monoinfected patients and 
HIV/HCV-coinfected patients; the second aim of this study 
was to evaluate the reliability of a model (linear predictor) that 
included clinical variables in predicting LS value.
Patients and methods
We retrospectively enrolled patients into this study 
based on the following eligibility criteria: 1) age over 
18 years; 2) diagnosis of chronic HIV infection; 3) hepatitis 
B serum antigen (HBsAg)-negative; 4) HCV treatment-
naïve or previously treated relapsers or non-responders; 
5) regular viro-immunological follow up of the HIV disease 
during at least the 12  months before TE; 6) no acute HCV 
infection; 7)  no alcohol abuse; 8) no didanosine, stavudine 
or zidovudine therapy; and 9) valid TE performed between 
December 1, 2013, and September 30, 2015. Patients 
were excluded from the study if they showed a sustained 
virological response (SVR), experienced a spontaneous 
clearance of HCV, or had other known causes of liver disease 
or previous liver transplantation. Alcohol abuse was defined 
as the daily consumption of alcohol in doses of more than 
20 g/day for women and more than 30 g/day for men. This 
study was conducted in accordance with local legislation and 
received approval from the local Ethics Committee of Padova 
University Hospital (61946/15). Anonymous data were 
collected retrospectively.
Patients were either untreated for HIV infection or received 
ART according to the current international guidelines. 
Decisions on HIV therapy were made at the discretion of the 
treating physician; there were no restrictions on CD4+ cell 
count.
Patients were classified based on plasma HIV viremia 
(detectable or undetectable when TE was performed and in the 
12 months and the 36 months before TE) and on the presence 
of HCV infection (patients were either HCV-positive or 
HCV-negative). We defined T0 as the study time corresponding 
to the execution of TE, T1 as the study time corresponding to 
the 12-month period (short term) before TE and T2 as the 
study time corresponding to the 36-month period (long term) 
before TE. Plasma HIV viremia data during T2 were available 
for a subgroup of subjects.
Study of HIV and HCV infection
Plasma HIV-1 RNA levels were measured using blood 
samples at all visits; regular monitoring was defined as a visit 
frequency of at least every four months. We considered plasma 
HIV viremia to be undetectable when the viral load was below 
the limit of 50 copies/mL [6]. Only a single viral blip (an increase 
in the HIV RNA plasma viral load above 50  copies/mL but 
below 500 copies/mL, followed by an undetectable HIV RNA) 
was tolerated [18]; HIV viremia was classified as detectable if 
any other result was obtained.
Both naïve and HCV treatment-experienced patients were 
included. Previously failed antiviral treatment included therapy 
with interferon (standard or pegylated) as monotherapy or with 
ribavirin, according to the current international guidelines 
at the start of HCV treatment. Any virological response that 
was different from SVR was classified as having no response to 
antiviral treatment.
HCV RNA genotypes were determined using the VERSANT® 
HCV genotype 2.0 assay (INNOLiPA, Innogenetics, Belgium). 
HIV and HCV plasma viral loads (copies/mL and IU/mL, 
respectively) were evaluated using the Abbott Real-Time assay 
(Abbott Molecular Inc., Des Plaines, IL).
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Study of liver fibrosis
LS was measured by TE (FibroScan®; Echosens, Paris, 
France). Significant liver fibrosis was defined as an LS of at 
least 7.1 kPa [19,20]. At least 10 successful measurements were 
performed on each patient; the result was considered valid 
when the interquartile range was lower than 30% of the median 
and a minimum success rate of 60% was obtained. Patients had 
been fasting for at least 8 h when TE was performed. An expert 
examiner carried out the LS assessments [21].
Statistical analysis
Conventional descriptive statistics were applied to describe 
the characteristics of the HIV-monoinfected subjects and the 
HIV/HCV coinfected patients. Continuous data were expressed 
as mean and standard deviation and were compared using 
Student’s t-test, while categorical data were compared using 
Fisher’s exact test. In addition, the variables were submitted 
to a pairwise correlation analysis using Pearson’s linear model 
to outline the underlying link pattern in the study population, 
and a logistic regression analysis was performed using the 
value of LS>7.1 kPa as the dependent variable. Then, a linear 
regression model was set up with lkpa (LS value after log10 
transformation) as the dependent variable. The mathematical 
model is a linear predictor; the final result was the predicted 
value of TE (expressed as lkpa) in a single patient and it was 
obtained by using the algebraic sum of each clinical variable 
multiplied by its own coefficient and of the intercept value. 
A  locally weighted regression was applied for the empirical 
validation of the model. A regression analysis of predicted lkpa 
values versus observed lkpa values was also performed and 
the characteristics of the left outliers (patients with predicted 
values that were higher than or comparable to the observed 
values) and of the right outliers (patients with predicted values 
that were lower than the observed values) were analyzed 
using the chi-square test with no continuity correction and 
Student’s t-test. Analyses were conducted using Stata software 
version  14.0 (College Station, Texas), and a P-value <0.05 
guided the statistical interpretation.
Results
A total of 413  patients underwent a TE; a complete 
description of the selection process is summarized in Fig.  1. 
Overall, 251 of the 277 (90.6%) patients were suitable for the 
main analysis (T1 study time); 26 patients were not included in 
the study because of a discordant plasma HIV viremia result at 
T1 and at T0 (21 patients had successful virological suppression 
at T0 and detectable viremia 12 months before TE).
The group of 251 patients included 178 HIV-monoinfected 
patients (124 with undetectable HIV RNA and 54 with 
detectable HIV RNA) and 73 HIV/HCV coinfected subjects 
(54 with undetectable HIV RNA and 19 with detectable 
HIV RNA). The demographic and viro-immunological 
characteristics of all the patients included in the study are 
presented in Table 1. Patients with HIV/HCV coinfection had 
a significantly higher LS value (P<0.0001), a greater incidence 
of significant fibrosis (P<0.0001), higher AST and alanine 
aminotransferase values (P<0.0001), and a lower number of 
CD4+ cell counts at nadir (P=0.003).
The 36-month study period was available for 154 subjects 
(61.3%), including 41 subjects (26.6%) with HIV/HCV 
coinfection and 113 subjects (73.4%) with HIV monoinfection. 
Most patients were Caucasian (96.8%) and on ART (89.6%). 
The HCV genotype was available for 72 of the 73  patients 
with a 12-month study duration; 41 of these subjects (56.9%) 
had genotype  1 infection. The mean HCV RNA level was 
comparable in coinfected patients with detectable pHIV and 
with undetectable pHIV (1,021,736  IU/mL, 95% confidence 
interval [CI] 393,401-2,653,638 IU/mL and 1,216,888 IU/mL, 
95%CI 797,099-1,857,756 IU/mL, respectively; P=0.69). Only 
a few HIV/HCV patients (14 of 73, 19.2%) had been previously 
treated with an interferon-based regimen. The mean LS was 
higher in HIV/HCV-coinfected patients (P<0.0001); most 
HIV-monoinfected patients (91%) had an LS value ≤7.1 kPa. 
No significant differences in LS values were found between 
patients classified as having detectable or undetectable plasma 
HIV viremia, while HIV/HCV patients had higher LS values 
than monoinfected subjects, regardless of plasma HIV viremia 
Figure 1 Flow chart describing the selection of the study patients 
1Alcohol abuse in 5 patients 
2Therapy with didanosine, stavudine or zidovudine in 3 patients 
TE, transient elastography
19 pts HBsAg positive1
413 TE performed
5 invalid TE
408 valid TE
5 patients with acute HCV infection
3 pts with liver transplantation
51 follow-up tests
23 pts with HCA RNA negative
30 pts with no regular monitoring2
277 patients enrolled
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(Fig.  2). There was a significant correlation between lkpa 
and age (P=0.025), HCV coinfection (P<0.0001) and AST 
(P<0.0001). The quadratic variable “bmi2” was added to the 
linear regression model in order to investigate the hypothesis 
of a non-linear correlation between lkpa and body mass index 
(BMI) and this hypothesis was confirmed (P=0.026); the other 
variables failed to reach significant P-values, including the 
successful suppression of HIV viremia at T1 and T2. This last 
finding was confirmed using logistic regression; this statistical 
approach revealed a positive correlation between an LS value 
>7.1 kPa and BMI (P=0.006), BMI as a quadratic variable 
(P=0.003), HCV coinfection (P<0.0001 and AST (P=0.001). 
The final linear regression model data are reported in Table 2; 
the mean predicted values were 4.69 kPa (95%CI 4.44-4.95 
kPa) in patients with HIV monoinfection and 8.39 kPa (95%CI 
7.70-9.15 kPa) in subjects with HIV/HCV coinfection. Fig. 3 
depicts the effects of HCV infection and BMI on the original 
LS data and on the model-based predictions.
Following the linear regression model, an analysis was 
performed to describe bivariate normal distributions for 
predicted and observed LS values in patients with and 
without HCV coinfection. Two subgroups of outliers were 
identified in the group with HIV monoinfection (8  patients 
in each subgroup, 9% of HIV-monoinfected patients) (Fig. 4). 
The predicted LS values included in the left outlier group 
were higher than or comparable to the observed LS values; 
conversely, the predicted LS data in the right outlier group 
were lower than the observed LS values. Patients included in 
the right outlier cohort had more frequent undetectable plasma 
HIV RNA (62.5% versus 12.5%, P=0.03) and lower mean AST 
(33 U/l versus 89 U/l, 95%CI of the difference 40-81 U/l, 
P<0.0001. Notably, the mean BMI was greater than 25 in both 
left outlier (28.6) and right outlier (29.6) groups (95%CI for 
combined groups 26.7-31.4).
Discussion
We performed a linear model analysis to describe the 
correlations between clinical and viro-immunological 
variables and LS measurement (LSM) in a cohort of 
patients with HIV infection or with HIV/HCV coinfection, 
focusing on the role of plasma HIV viremia detectability or 
undetectability during two different study periods (12 and 
36  months before LSM). In the overall study population, 
no correlation was reported for either HIV-monoinfected 
patients or subjects with HCV coinfection. Consistently with 
our results, Merchante et al [15] reported that HIV viremia 
(binary variable, <200 copies/mL versus >200 copies/mL) 
at the time of TE is not a factor that is associated with an 
abnormal LS value (defined as >7.2 kPa in a cross-sectional 
study including only HIV-monoinfected subjects). Conversely, 
Mohr et al [22] showed that detectable HIV viremia for a 
Table 1 Characteristics of the 178 HIV-monoinfected subjects and of the 73 HIV HCV coinfected patients
Variables HCV negative
(178 patients)
HCV positive
(73 patients)
P-value
Age (years)1 47 (11) 48 (7) 0.631
Male sex, n (%) 159 (89.3) 57 (78.1) 0.019
BMI1 24.3 (3.6) 23.4 (3.3) 0.063
Patients with BMI≥30, n (%) 14 (7.8) 4 (5.5) 0.59
LS (kPa)1 4.6 (1.4) 8.4 (1.6) <0.0001
Patients with LS>7.1 kPa, n (%) 16 (9) 40 (54.8) <0.0001
CD4+ cell count at nadir (cells/mm3)1 361 (261) 263 (151) 0.003
CD4+ cell count at T0 (cells/mm3)1 634 (296) 606 (333) 0.51
AST (U/L)1 29 (16) 60 (33) <0.0001
ALT (U/L)1 32 (34) 69 (39) <0.0001
Patients on ART, n (%) 156 (87.6) 69 (94.5) 0.116
Patients with plasma HIV RNA undetectable, n (%)2 123 (78.9) 53 (76.8) 0.73
PI as third drug, n (%)2 99 (63.5) 49 (71) 0.27
HIV RNA at T02 (copies/mL)3 8979
(2311-23731)
962
(101-30553)
0.191
Significant P-values are in bold
1 mean and SD
2 percentage with respect to patients on ART 
3 median and 95%CI in patients with detectable plasma HIV RNA 
ALT, alanine aminotransferase; ART, antiretroviral treatment; AST, aspartate aminotransferase; BMI, body mass index; LS, liver stiffness; PI, protease inhibitor
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period of more than 2  years was associated with higher LS 
values in naïve HIV-monoinfected patients; in this study, the 
subjects were classified as having plasma HIV viremia either 
greater than 40 copies/mL or undetectable. We were able to 
evaluate the role of two periods of different length (12 and 
36 months) providing the same result. Moreover, the enrolled 
HIV viremic patients were both naïve and unresponsive to 
ART; a possible effect of an ART regimen with suboptimal 
efficacy cannot be excluded. Notably, both in our study and 
in Mohr’s, there were no correlations found in patients with 
HIV/HCV coinfection.
The plasma HIV viremia burden may play a role in 
explaining the differences between these results. Matthews 
et  al [23] showed an association between HIV viremia and 
LS value in a population of naïve patients who had a median 
HIV RNA log10 copies of 4.4 (3.9 log10 copies/mL in our study); 
only 3.9% of the participants had undetectable viremia (the 
cutoff was set at ≤400 copies/mL, while it was 50 copies/mL 
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Figure 2 Liver stiffness values in HIV-monoinfected patients and in HIV/HCV patients according to plasma HIV RNA detectability or 
undetectability in the 12 months or 36 months before transient elastography
LS, liver stiffness; kPa, kilopascal; pHIV, plasma HIV RNA; m, months
Table 2 Linear regression model with lkpa (liver stiffness absolute value after log10 transformation), as dependent variable
lkpa Coefficient Standard error t P>t 95%CI
Age (years) 0.0021796 0.0009666 2.25 0.025 0.0002748 0.0040844
Male sex −0.0366232 0.0325936 −1.12 0.262 −0.1008542 0.0276077
HIV 0.0202064 0.0250061 0.81 0.420 −0.0290721 0.0694849
HCV 0.1490692 0.0265554 5.61 0.000 0.0967376 0.2014008
Nadir CD4 −0.000035 0.0000513 −0.68 0.496 −0.0001362 0.0000662
CD4 −7.53E-06 0.0000401 −0.19 0.851 −0.0000865 0.0000714
BMI -0.0530044 0.0280289 −1.89 0.060 −0.1082398 0.0022309
BMI2 0.0012249 0.0005458 2.24 0.026 0.0001492 0.0023006
AST 0.0035958 0.0004461 8.06 0.000 0.0027167 0.0044749
Intercept 1.053148 0.3531909 2.98 0.003 0.357129 1.749167
Prob > F=0.0000. R2=0.4971
ALT, alanine aminotransferase; ART, antiretroviral treatment; AST, aspartate aminotransferase; BMI, body mass index; CD4, CD4+ cell count (cells/mm3); 
HIV, plasma HIV RNA undetectable; LS, liver stiffness; Nadir CD4: CD4+ cell count (cells/mm3) at nadir; Std. Err, standard error 
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in our study). Moreover, higher LS values were correlated 
with higher log10 HIV RNA values and a threshold effect 
that was defined as the upper limit of the first two quartiles 
(19,999 copies/mL) was described; our median values were 
under this threshold (8979 copies/mL in HIV-monoinfected 
patients and 962 copies/mL in HIV/HCV-coinfected subjects). 
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Figure 3 Linear model representation including the three main variables, log10(kPa), BMI, and HCV. The Figure depicts the effects of HCV infection 
and BMI on the Fibroscan values on the original data and on the model-based predictions
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Figure 4 Graph describing the linear fit between predictions and observed Fibroscan values. 
The reference line where predictions correspond to observations is also shown. The ellipses indicate bivariate normal distributions for predictions 
and observed Fibroscan values. Each of them correspond to a probability of 86%; they account for the two subpopulations according to HCV 
status. Outliers, left: green; outliers, right, magenta; 
Obs, observations; HCV 0, HIV patient HCV-negative; HCV 1, HIV patient HCV-positive; Out, outliers 
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A  role for the HIV RNA level in determining liver disease 
was reported by Towner et al [24] in a cohort study involving 
20,775 HIV-positive subjects; the authors demonstrated a 
higher rate of hepatic dysfunction and hepatic dysfunction-
related death in the case of plasma HIV RNA>500 copies/mL, 
while the risk increased with higher HIV RNA levels. A plasma 
HIV RNA value <500 copies/mL was shown to protect against 
liver fibrosis progression (determined with FIB-4 and AST-to-
platelet ratio index scores) in a cohort of naïve patients who 
were starting highly active ART [25]; conversely, a median 12% 
increase in FIB-4 was associated with a 1 log increase in HIV 
RNA in the study conducted by Forrester et al [26].
The course of liver disease is largely unpredictable on a 
case-by-case basis, because liver fibrosis is a multifactorial 
process and the viscoelasticity of the liver may be influenced 
by inflammatory processes, as demonstrated in post–liver-
transplant acute cellular rejection [27]. Our statistical model 
identified a group of HIV-monoinfected patients with LS values 
that were discordant with respect to the predicted values; HCV 
infection had a much stronger hepatic damage capacity than 
did HIV infection, and this probably justified the absence of 
coinfected patients among the left and right outliers. The mean 
BMI was ≥25 in the left outliers (the predicted LS value was 
higher than or comparable to the observed LS value) and in 
the right outliers (the observed LS value was higher than the 
predicted value); increased levels of inflammatory mediators 
have been described in subjects with HIV who were overweight 
and this could have perturbed the model [28]. Liver fibrosis 
is associated with higher BMI values in HIV-monoinfected 
subjects [29], and we confirmed this correlation using logistic 
regression in our cohort; however, both left and right outlier 
subjects were overweight. Almost all right outlier patients 
(87.5%) had plasma HIV RNA levels that were undetectable in 
the 12 months before TE, which is in apparent contradiction 
to the absence of a correlation between the LS value and HIV 
viremia. Furthermore, HIV RNA is not the only virological 
parameter that can be used to evaluate HIV infection; cellular 
HIV DNA constitutes the viral reservoir and is detectable in 
peripheral mononuclear blood cells in patients with long-
term suppressed viremia [30-32]. Recently, HIV DNA was 
also identified in the hepatic tissue of patients who died while 
they were on ART and who had undetectable levels of HIV 
RNA [33].
TE results are currently interpreted as a range in clinical 
practice, since this provides a more reliable correlation with the 
degree of fibrosis [34]. We choose to explore the absolute LS 
value in our HIV-monoinfected patients in order to highlight 
the differences in a population whose LS values were almost 
all included in the F0-F1 class of fibrosis (LSM<7.1). No 
selection bias was evident; our study population had an LSM 
value comparable to that of previously described cohorts of 
HIV-positive patients, ranging from 3.9-4.9 kPa [14,15,35]. 
The main limits of our study are the influence of intra-observer 
TE reproducibility and the low number of outlier patients. All 
of the TEs were performed by the same expert operator and 
only 5 of the 413  patients who were screened (1.2%) were 
excluded from the study because of an invalid TE, so good 
reproducibility was expected [36]. One strength of our study 
was the careful selection of patients; there were no HBsAg-
positive subjects included, patients with HCV coinfection 
were all HCV RNA-positive and almost all of the patients were 
Caucasian. The independent predictive role of race has scarcely 
been studied, but Hispanic/Latino ethnicity was independently 
associated with higher TE scores in HIV patients [23], and HIV 
coinfection was predictive of early fibrosis in HCV positive 
African Americans [37].
In conclusion, the present study demonstrated that LS did 
not correlate with ongoing HIV replication during 12-  and 
36-month study periods in immunocompetent HIV/HCV-
coinfected patients and in HIV-monoinfected subjects.
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